1. Synergistic antitumor effect of anti-CD40/CpG and 14
Synergistic antitumor effect of anti-CD40/CpG and IL-2 IC/anti-CTLA-4.
Synergistic antitumor effect of anti-CD40/CpG and IL-2 IC/anti-CTLA-4. B78 melanoma cells (2 × 106) were injected s.c. into C57BL/6 mice on day 0. Anti-CD40 (500 μg) was injected i.p. on day 23; CpG (25 μg) was injected IT on days 26, 28, and IL-2 IC (25 μg) was given IT on days 26–30; anti–CTLA-4 (200 mg) was injected i.p. on days 26, 28, 30, 33, 35, and 40. Results are shown as means ± SEM of tumor volumes (A) and survival (B) of five mice per group. (A) Differences between a combined treatment versus separate treatment groups are shown. (C) C57BL/6 mice bearing B78 tumors received combined treatment with anti-CD40/CpG and IC/anti–CTLA-4 (clone 9D9, IgG2a) as described in (A) up to day 33. On day 34, tumors were removed, and single-cell suspensions were evaluated for indicated immune cells by flow cytometry. Results are shown as means ± SEM of five mice per group. (D) C57BL/6 mice were injected s.c. with 5 × 105 B16 or B16-GD2 cells. Anti-CD40 was injected i.p. on day 7; CpG was injected IT on days 10, 12, and IL-2 IC was given IT on days 10–14; anti–CTLA-4 (clone 9D9, IgG2a) was injected i.p. on days 10, 12, 14, 17, 19, and 21. Control mice received no treatment. Results are shown as survival of five mice per group. Differences between the control versus treatment groups are shown. Unless stated otherwise, statistical differences are indicated for the last day on the graph. *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
Alexander L. Rakhmilevich et al. J Immunol 2017;198:
Copyright © 2017 by The American Association of Immunologists, Inc.